The emergence of chimeric antigen receptor (CAR) T-cell therapy that targets B-cell maturation antigen (BCMA) has revolutionized the treatment landscape for R/R MM, particularly in patients with limited therapeutic options (5). This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.